Published in Chest on May 01, 1999
Exhaled nitric oxide measurements: clinical application and interpretation. Thorax (2006) 2.01
Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases. Thorax (2002) 1.02
Interstitial lung disease in systemic sclerosis. Lung (2007) 0.94
Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol (2003) 0.89
Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis. Thorax (2007) 0.84
Exhaled nitric oxide in sarcoidosis. Thorax (2005) 0.82
Exhaled nitric oxide in diagnosis and management of respiratory diseases. Ann Thorac Med (2009) 0.81
Application of nitric oxide measurements in clinical conditions beyond asthma. Eur Clin Respir J (2015) 0.80
Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. BMC Pulm Med (2013) 0.80
Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res (2005) 0.79
Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol (2007) 0.76
Inflammatory markers: exhaled nitric oxide and carbon monoxide during the ovarian cycle. Inflammation (2012) 0.75
Breath tests in respiratory and critical care medicine: from research to practice in current perspectives. Biomed Res Int (2013) 0.75
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease. Can Respir J (2017) 0.75
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996) 5.53
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J (2005) 5.24
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet (2001) 3.48
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med (1999) 3.44
Asthma as an axon reflex. Lancet (1986) 3.26
Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet (1982) 3.21
Exhaled markers of pulmonary disease. Am J Respir Crit Care Med (2001) 3.14
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J (1997) 2.79
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax (1998) 2.71
Exacerbations of chronic obstructive pulmonary disease. Eur Respir J (2007) 2.65
Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis (1987) 2.64
Cytokines in asthma. Thorax (1999) 2.64
The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (2000) 2.63
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax (1993) 2.33
Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med (2000) 2.33
Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1996) 2.32
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med (1992) 2.32
Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 2.28
Primary Pneumocystis carinii and cytomegalovirus infections. Lancet (1981) 2.23
Circulating catecholamines in exercise and hyperventilation induced asthma. Thorax (1981) 2.22
Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology (2001) 2.20
Exhaled carbon monoxide in childhood asthma. J Pediatr (1999) 2.19
Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med (1998) 2.19
Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J (2001) 2.18
Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J (2004) 2.18
A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1999) 2.08
STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 2.06
Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J (2002) 2.04
Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med (2000) 2.03
The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br J Pharmacol (1985) 1.98
Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun (2004) 1.98
Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax (2004) 1.96
Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun (1994) 1.96
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.94
Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med (1999) 1.92
Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med (1997) 1.91
A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax (1981) 1.90
Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis (1985) 1.89
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol (2009) 1.89
Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med (1995) 1.84
A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med (1997) 1.84
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J (2003) 1.81
Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J (1995) 1.80
Brittle asthma. Thorax (1998) 1.77
Importance of inhaler devices in the management of airway disease. Respir Med (2007) 1.76
Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. Arthritis Rheum (1999) 1.76
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax (2001) 1.76
Airway inflammation after controlled exposure to diesel exhaust particulates. Am J Respir Crit Care Med (2000) 1.75
Circulating catecholamines in acute asthma. Br Med J (Clin Res Ed) (1985) 1.73
Is immunotherapy for asthma worthwhile? N Engl J Med (1996) 1.72
Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol (1997) 1.70
Effect of inhaled corticosteroids on bones and growth. Eur Respir J (1998) 1.68
Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax (2004) 1.68
Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J (2003) 1.68
Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med (1995) 1.67
Pseudo-steroid resistant asthma. Thorax (1999) 1.67
Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol (1992) 1.67
Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med (1995) 1.67
Late response to allergen is associated with increased concentrations of tumor necrosis factor-alpha and IL-5 in induced sputum. J Allergy Clin Immunol (1997) 1.65
Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med (1998) 1.65
Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med (1996) 1.65
Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis (1986) 1.65
Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax (2009) 1.65
Exhaled nitric oxide: a new lung function test. Thorax (1996) 1.64
Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med (2001) 1.63
Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun (1997) 1.63
Adenosine as a vasodilator in primary pulmonary hypertension. Circulation (1991) 1.63
Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax (1998) 1.63
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax (2008) 1.62
Bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol (1985) (1985) 1.61
Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.60
Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J (2009) 1.59